WO1996029045A1 - Compositions for the treatment of dandruff - Google Patents

Compositions for the treatment of dandruff Download PDF

Info

Publication number
WO1996029045A1
WO1996029045A1 PCT/US1996/003988 US9603988W WO9629045A1 WO 1996029045 A1 WO1996029045 A1 WO 1996029045A1 US 9603988 W US9603988 W US 9603988W WO 9629045 A1 WO9629045 A1 WO 9629045A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
treatment
dandruff
composition
antifungal agent
Prior art date
Application number
PCT/US1996/003988
Other languages
French (fr)
Inventor
Avi Dascalu
Yoram Oron
Original Assignee
Ramot University Authority For Applied Research And Industrial Development Ltd.
Shoshan, Herbert, Z.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot University Authority For Applied Research And Industrial Development Ltd., Shoshan, Herbert, Z. filed Critical Ramot University Authority For Applied Research And Industrial Development Ltd.
Priority to US08/913,650 priority Critical patent/US6075017A/en
Priority to AU55261/96A priority patent/AU5526196A/en
Publication of WO1996029045A1 publication Critical patent/WO1996029045A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/23Sulfur; Selenium; Tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/006Antidandruff preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair

Definitions

  • the invention relates to pharmaceutical compositions for use in the treatment of seborrheic dermatitis of the scalp.
  • Dandruff seborrheic dermatitis of the scalp, is a common disease involving 3-5% of the population. Dandruff is, in many cases, the precursor of alopecia (baldness) and constitutes a chronic and almost intractable cosmetical and social inconvenience. The pathophysiology of the disease remains unknown, although it is known to involve a hyperproliferat ⁇ ive state of the skin, a limited inflammatory process, and a secondary microbial colonization by the lipophilic yeast Pityrosporum, which is abundant and significantly ovcrpopulated on the scalp of seborrheic patients. Dandruff is a chronic and almost incurable disease. Available treatments result only in short term effects with an eventual recurrence of the disease.
  • a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
  • a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
  • the present invention provides by a first of its aspects a composition, e g in the form of a hair shampoo, for the treatment of dandruff or of symptoms associated therewith, comprising in combination an effective amount of at least one cytotoxic agent and an effective amount of at least one antifungal agent, together with a carrier, a diluent or an excipient
  • effective amount means to denote an amount of an agent effective in achieving a therapeutic result in the treatment of dandruff, such as alleviation of itching, a decrease in the amount of scales, a reduction in the rate of hair loss, a reduction in scalp redness, etc.
  • cytotoxic agent as used herein means to denote an agent which inhibits proliferation of keratinocytes skin cells.
  • antifungal agent will be used to denote an agent which is specifically active in inhibiting growth of fungus and the fungus' ability to colonize the skin, which includes, inter alia, agents which are destructive to fungi, or active in suppressing growth of fungus or affect their ability to reproduce
  • cytotoxic agent refers to agents which arc known in the art primarily by having cytotoxic activity
  • antifungal agent refers to agents which are known in the art primarily by their antifungal activity
  • cytotoxic agents useful in accordance with the invention are coal tars, selenium sulfide, zinc pyrithione or the like.
  • the preferred cytoxic agent is coal tar, typically included in the composition in concentration of 1-5%.
  • antifungal agents useful in accordance with the invention include imidazoles, ciclopiroxolamines and metronidazolcs.
  • the imidazoles which arc preferred in accordance with the invention, include ketoconozole, bifonazole, itraconazolc, cconazole, clotrimazole, miconazole, oxiconazole, isoconazolc and the like. From the imidazoles, ketoconozole is particularly preferred.
  • the antifungal agent is included in the composition in a concentration of 0.5-5%
  • the present invention further provides the use of said cytotoxic agent in combination with said antifungal agent for the preparation of a composition, e.g. a medical hair shampoo, for the treatment of dandruff.
  • a composition e.g. a medical hair shampoo
  • a further aspect of the invention is concerned with the treatment of individuals suffering from dandruff by combined application to the scalp of such individuals of said cytotoxic agent and of said antifungal agent.
  • the individuals may be treated by the use of a single composition, e.g. in the form of a hair shampoo, comprising both agents.
  • the individuals may be treated by a combination of two different compositions, one comprising said cytotoxic agent and the other said antifungal agent. The above described combination may be applied 3-4 times during the first week from the start of the treatment, and 1-2 times a week, thereafter.
  • the present invention also pertains to a package comprising at least two compositions, one comprising said antifungal agent and the other said cytotoxic agent, optionally with instructions for use in said method.
  • Example 1 A group of six patients (ages 17-38) with a severe case of dandruff were on a regular bi-weekly anti seborrheic treatment prior to the onset of the experiment. During the experiment they were treated with a combination of the following two compositions: a. a composition comprising 1.8% coal tar. b. a solution comprising 2% kctoconazole.
  • the patients were instructed to apply the two compositions, one after the other, in an amount sufficient to cover the entire scalp.
  • the patients were instructed to apply the compositions on days 1 , 3, 6 and 9.
  • the patients' conditions were examined after 14 or 30 days following the onset of treatment.
  • the patients' conditions were evaluated by the following criteria: (i) scaling - existence of scales on the scalp, typically at the temporal area; (ii) itching - based on the patient's subjective feeling; (iii) severity - overall assessment of the dandruff disease situation, taking into account the skin redness as an indication of inflammatorv conditions. - D -
  • Example 1 A group of three patients who had no record of treatment for dandruff prior to the onset of the experiment, was given the same treatment as in Example 1. The patients' condition was as severe as in Example 1.

Abstract

Seborrheic dermatitis of the scalp is treated by a combination of a cytotoxic agent and antifungal agent.

Description

COMPOSITIONS FOR THE TREATMENT OF DANDRUFF
FIELD OF THE INVENTION
The invention relates to pharmaceutical compositions for use in the treatment of seborrheic dermatitis of the scalp.
BACKGROUND OF THE INVENTION
Dandruff, seborrheic dermatitis of the scalp, is a common disease involving 3-5% of the population. Dandruff is, in many cases, the precursor of alopecia (baldness) and constitutes a chronic and almost intractable cosmetical and social inconvenience. The pathophysiology of the disease remains unknown, although it is known to involve a hyperproliferat¬ ive state of the skin, a limited inflammatory process, and a secondary microbial colonization by the lipophilic yeast Pityrosporum, which is abundant and significantly ovcrpopulated on the scalp of seborrheic patients. Dandruff is a chronic and almost incurable disease. Available treatments result only in short term effects with an eventual recurrence of the disease.
A traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent. However, as _ **. _
pointed out heretofore no treatment provides long term alleviation from the symptoms of this disease
It is an object of the invention to provide a composition useful in the treatment of dandruff or symptoms associated therewith. It is another object of the invention to provide a method for alleviation of dandruff or symptoms associated therewith.
GENERAL DESCRIPTION OF THE INVENTION
The present invention provides by a first of its aspects a composition, e g in the form of a hair shampoo, for the treatment of dandruff or of symptoms associated therewith, comprising in combination an effective amount of at least one cytotoxic agent and an effective amount of at least one antifungal agent, together with a carrier, a diluent or an excipient The term "effective amount" as used herein means to denote an amount of an agent effective in achieving a therapeutic result in the treatment of dandruff, such as alleviation of itching, a decrease in the amount of scales, a reduction in the rate of hair loss, a reduction in scalp redness, etc. The term "cytotoxic agent" as used herein means to denote an agent which inhibits proliferation of keratinocytes skin cells. The term "antifungal agent" will be used to denote an agent which is specifically active in inhibiting growth of fungus and the fungus' ability to colonize the skin, which includes, inter alia, agents which are destructive to fungi, or active in suppressing growth of fungus or affect their ability to reproduce
It will be appreciated by the artisan that the agents which are cytotoxic may also have some anti-fungal activity and an anti-fungal agent may also have some cytotoxic activity Thus, the term "cytotoxic agent" refers to agents which arc known in the art primarily by having cytotoxic activity and the term "antifungal agent" refers to agents which are known in the art primarily by their antifungal activity.
In the following description reference will at times be made to concentrations given in percent (%), this indication meaning the number of weight units of any ingredient in hundred weight units of an entire composition.
Examples of cytotoxic agents useful in accordance with the invention are coal tars, selenium sulfide, zinc pyrithione or the like. The preferred cytoxic agent is coal tar, typically included in the composition in concentration of 1-5%.
Examples of antifungal agents useful in accordance with the invention include imidazoles, ciclopiroxolamines and metronidazolcs. The imidazoles, which arc preferred in accordance with the invention, include ketoconozole, bifonazole, itraconazolc, cconazole, clotrimazole, miconazole, oxiconazole, isoconazolc and the like. From the imidazoles, ketoconozole is particularly preferred. Typically, the antifungal agent is included in the composition in a concentration of 0.5-5%
The present invention further provides the use of said cytotoxic agent in combination with said antifungal agent for the preparation of a composition, e.g. a medical hair shampoo, for the treatment of dandruff.
A further aspect of the invention is concerned with the treatment of individuals suffering from dandruff by combined application to the scalp of such individuals of said cytotoxic agent and of said antifungal agent. The individuals may be treated by the use of a single composition, e.g. in the form of a hair shampoo, comprising both agents. Alternatively, the individuals may be treated by a combination of two different compositions, one comprising said cytotoxic agent and the other said antifungal agent. The above described combination may be applied 3-4 times during the first week from the start of the treatment, and 1-2 times a week, thereafter.
The present invention also pertains to a package comprising at least two compositions, one comprising said antifungal agent and the other said cytotoxic agent, optionally with instructions for use in said method.
In the following the invention will be illustrated with reference to a non-limiting specific embodiment described in the Example below. Example 1 : A group of six patients (ages 17-38) with a severe case of dandruff were on a regular bi-weekly anti seborrheic treatment prior to the onset of the experiment. During the experiment they were treated with a combination of the following two compositions: a. a composition comprising 1.8% coal tar. b. a solution comprising 2% kctoconazole.
The patients were instructed to apply the two compositions, one after the other, in an amount sufficient to cover the entire scalp. The patients were instructed to apply the compositions on days 1 , 3, 6 and 9.
The patients' conditions were examined after 14 or 30 days following the onset of treatment.
The patients' conditions were evaluated by the following criteria: (i) scaling - existence of scales on the scalp, typically at the temporal area; (ii) itching - based on the patient's subjective feeling; (iii) severity - overall assessment of the dandruff disease situation, taking into account the skin redness as an indication of inflammatorv conditions. - D -
For the above criteria a score was given by using the following scale:
0 non existing
1 minimal o moderate
3 severe
The results are shown in the following Table 1
Table 1
Patient Age Sex Scale Itch Severity Day No.
B* A+ B* A+ B* A+
1 oo m o 0 o 0 2 0 30
38 m 1 •-
_> 0 1 14
- 23 m o 0 o 0 o 0 14
4 27 m o 0 o 0 o 0 14
5 17 f 3 1 J 1 3 1 14
6 37 m o 0 0 o 0 14,30
B - before treatment according to the present invention; A - after treatment.
The results of Table 1 show clearly that following treatment, there is a considerable decrease in scale formation, reduction in scalp redness and itching in all treated patients. The subjects reported that the improvements started within about five days from the onset of the treatment. Furthermore, this combined treatment brought to a remission of the disease's symptoms for about two weeks in some of the patients, after the treatment was terminated, as can be seen in the patients tested after thirty days. Example 2:
A group of three patients who had no record of treatment for dandruff prior to the onset of the experiment, was given the same treatment as in Example 1. The patients' condition was as severe as in Example 1.
The results are shown in the following Table 2:
Table 2
Patient Age Sex Scale Itch Severity Day
No.
B* A^ B* A+ B* A+
1 32 f 1 0 1 0 1 0 30 o 27 f o 1 3 1 o 1 30
3 24 f 1 0 1 0 1 0 14
* B - before treatment according to the present invention;
+ A - after treatment.
Again it is clearly demonstrated that the combined application of the two compositions, results in a substantial disappearance of the symptoms accompanying dandruff disease.

Claims

CLAIMS:
1. A composition for treatment of seborrheic dermatitis of the scalp, comprising, in combination, an effective amount of at least one cytotoxic agent and an effective amount of at least one antifungal agent, together with a carrier, diluent or excipient.
2. A composition according to claim 1, wherein the cytotoxic agent is selected from the group consisting of coal tars, selenium sulfide and zinc pyrithione.
3. A composition according to claim 2, comprising 1 to 5% of sa;d cytotoxic agent.
4. A composition according to claim 1, wherein the antifungal agent is selected from the group consisting of imidazoles, ciclopiroxolamines and metronidazoles.
5. A composition according to claim 4, wherein the antifungal agent is selected from the group consisting of ketoconazole, bifonazole, itraconaz- ole, econazole, clotrimazole, miconazole, oxiconazole and isoconazole.
6. A composition according to claim 4, comprising 0.5 to 5% of said antifungal agent.
7. Use of at least one cytotoxic agent, together with at least one antifungal agent for the preparation of a composition for the treatment of dandruff.
8. A method for treating dandruff comprising applying to the scalp an effective amount of at least one cvtotoxic agent in combination with at least one antifungal agent.
9. A package which comprises at least one composition comprising a cytotoxic agent and at least one composition comprising an antifungal agent.
10. A package according to claim 9, which comprises instructions for use in the method of claim 8.
PCT/US1996/003988 1995-03-21 1996-03-20 Compositions for the treatment of dandruff WO1996029045A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/913,650 US6075017A (en) 1995-03-21 1996-03-20 Compositions for the treatment of dandruff
AU55261/96A AU5526196A (en) 1995-03-21 1996-03-20 Compositions for the treatment of dandruff

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL113057 1995-03-21
IL11305795A IL113057A (en) 1995-03-21 1995-03-21 Compositions for the treatment of dandruff

Publications (1)

Publication Number Publication Date
WO1996029045A1 true WO1996029045A1 (en) 1996-09-26

Family

ID=11067236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/003988 WO1996029045A1 (en) 1995-03-21 1996-03-20 Compositions for the treatment of dandruff

Country Status (3)

Country Link
AU (1) AU5526196A (en)
IL (1) IL113057A (en)
WO (1) WO1996029045A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029733A1 (en) * 1996-02-16 1997-08-21 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a sulfur compound
WO1999030675A1 (en) * 1997-12-18 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
WO2000006144A1 (en) * 1998-07-27 2000-02-10 Howard Murad Pharmaceutical compositions and methods for managing scalp conditions
DE19938404A1 (en) * 1999-08-13 2001-02-22 Clariant Gmbh Cosmetic preparations
US6469033B1 (en) 1996-09-27 2002-10-22 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
US6916479B2 (en) 1997-04-14 2005-07-12 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
US7018656B2 (en) 1996-09-27 2006-03-28 Aventis Pharma Deutschland Gmbh Antimycotic gel with high active substance release
US7981909B2 (en) 1996-09-27 2011-07-19 Medicis Pharmaceutical Corporation Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
US4518789A (en) * 1982-06-30 1985-05-21 Yu Ruey J Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294852A (en) * 1973-11-01 1981-10-13 Johnson & Johnson Skin treating compositions
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
US4518789A (en) * 1982-06-30 1985-05-21 Yu Ruey J Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029733A1 (en) * 1996-02-16 1997-08-21 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a sulfur compound
US6469033B1 (en) 1996-09-27 2002-10-22 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
US7018656B2 (en) 1996-09-27 2006-03-28 Aventis Pharma Deutschland Gmbh Antimycotic gel with high active substance release
US7026337B2 (en) 1996-09-27 2006-04-11 Aventis Pharma Deutschland Gmbh Antimycotic gel having high active compound release
US7981909B2 (en) 1996-09-27 2011-07-19 Medicis Pharmaceutical Corporation Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US6916479B2 (en) 1997-04-14 2005-07-12 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
WO1999030675A1 (en) * 1997-12-18 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
US6099870A (en) * 1997-12-18 2000-08-08 Johnson & Johnson Consumer Companies, Inc. Methods for improving the health of hair and scalp
WO2000006144A1 (en) * 1998-07-27 2000-02-10 Howard Murad Pharmaceutical compositions and methods for managing scalp conditions
DE19938404A1 (en) * 1999-08-13 2001-02-22 Clariant Gmbh Cosmetic preparations
WO2001012140A1 (en) * 1999-08-13 2001-02-22 Clariant Gmbh Cosmetic preparations
US6663875B2 (en) 1999-08-13 2003-12-16 Clariant Gmbh Hair preparation for the treatment of dandruff

Also Published As

Publication number Publication date
AU5526196A (en) 1996-10-08
IL113057A (en) 1999-01-26
IL113057A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
Faergemann Management of seborrheic dermatitis and pityriasis versicolor
Healy et al. PUVA treatment for alopecia areata—does it work? A retrospective review of 102 cases
EP0500745B1 (en) Metal-peptide compositions and cosmetic methods for stimulating hair growth
EP0961609B1 (en) Methods for improving the health of hair and scalp
EP0673643B1 (en) Cosmetic composition containing an association of superoxide dismutase and porphyrine
EP0770376B1 (en) Use of a substance P antagonist in a topical composition as antiperspirant
WO1996029045A1 (en) Compositions for the treatment of dandruff
US6673842B2 (en) Method of treating onychomycosis
US6075017A (en) Compositions for the treatment of dandruff
DE3619904A1 (en) AGENT TO BE ORALED
US20030181526A1 (en) Method of treating onychomycosis
WO1999044579A2 (en) Use of a compound inhibiting the activity of a sodium channel and a calcium channel in a composition for topical use
Ive An overview of experience with ketoconazole shampoo
FR2769838A1 (en) Use of azole derivatives to treat inflammation and sensitive skins
Golf et al. Systemic short-term fibrinolysis with high-dose streptokinase in acute myocardial infarction: time course of biochemical parameters
EP1014928A2 (en) Use of a serotonin antagonist or agonist respectively specific of the 5ht 2? and 5ht 1d? receptor in a cosmetic or dermatological composition for sensitive skin and resulting composition
JPH0112725B2 (en)
WO2023217936A1 (en) Novel use of a blend of sugars comprising psicose, mannose, fructose and glucose
McGavack et al. A clinical investigation of beta-morpholino-ethyl benzhydryl ether hydrochloride (linadryl) as an antihistamine agent
Simpson et al. The clinical evaluation of a new butyrophenone (WY-3457)
KR20220071218A (en) Combination of ciclopiroxolamine and piroctone olamine to combat dandruff
EP4011360A1 (en) Cosmetic complex for moisturizing skin, use of the cosmetic complex, cosmetic composition and skin moisturizing method
KR20090039458A (en) A composition using the hair containing chamaecyparis obtusa oil
DE3340878C2 (en) Orally applicable composition
AU2006203095A1 (en) Methods for improving the health of hair and scalp

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08913650

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA